Effect of Total Body Irradiation on Late Lung Effects: Hidden Dangers
Overview
Authors
Affiliations
Purpose: In our ongoing investigation into the consequences of a radiological terrorism or nuclear dispersion event, we assessed whether a dose range that is believed to be sub-threshold for the development of lung endpoints results in late pathological changes and, secondarily, whether those late changes affect the lung's ability to respond to subsequent challenge.
Materials And Methods: C57BL/6J mice received total body irradiation (0.5-10 Gy) and were followed for 6-18 months after irradiation. At 12 and 15 months, a subset of mice was exposed to a second challenge (aerosolised lipopolysaccharide [LPS]).
Results: Cytokines shown to be upregulated early (hours) following irradiation (interleukin [IL]6, keratinocyte chemoattractant [KC], IL1B, and IL1R2) demonstrated increases in messenger ribose nucleic acid (mRNA) expression at late time points, beginning at nine months. Although persistent, dose-dependent increases in T cell counts were seen, no other overt changes in pathophysiology were observed. Nonetheless, animals that were exposed to a secondary challenge at late time points demonstrated an increased inflammatory cell recruitment and persistence in response relative to controls.
Conclusions: We propose that, following doses that elicit little change in pathophysiology, sub-clinical radiation-induced injury increases the lungs' susceptibility to a secondary challenge, possibly through a radiation-induced alteration in the immune defense system.
Mitigating Viral Impact on the Radiation Response of the Lung.
Groves A, Paris N, Johnston C, Hernady E, Finkelstein J, Lawrence P Radiat Res. 2024; 202(3):552-564.
PMID: 39048109 PMC: 11610374. DOI: 10.1667/RADE-24-00103.1.
Safarbalou A, Ebrahimi F, Talebpour Amiri F, Hosseinimehr S Curr Pharm Des. 2024; 30(27):2179-2186.
PMID: 38874044 DOI: 10.2174/0113816128296224240530060011.
Global research trends in Total Body Irradiation: a bibliometric analysis.
Alqathami M, Khan M, Yoosuf A Front Oncol. 2024; 14:1370059.
PMID: 38737901 PMC: 11082912. DOI: 10.3389/fonc.2024.1370059.
Safarbalou A, Ebrahimi F, Talebpour Amiri F, Hosseinimehr S Curr Radiopharm. 2023; 17(1):38-45.
PMID: 37489775 DOI: 10.2174/1874471016666230725112319.
Clonal hematopoiesis, somatic mosaicism, and age-associated disease.
Evans M, Walsh K Physiol Rev. 2022; 103(1):649-716.
PMID: 36049115 PMC: 9639777. DOI: 10.1152/physrev.00004.2022.